ERBB2 and breast carcinoma: Seven prognostic factors of predicting cancer‐specific survival (CSS) for HER2‐positive breast cancer patients with bone metastases were identified, including age, brain metastases, liver metastases, lung metastases, PR status, surgery, and chemotherapy.